What Lipid Panel Tests Measure

When evaluating cardiovascular health, lipid profile testing is a cornerstone of preventive medicine. This blood test measures several key biomarkers that reflect the body’s fat metabolism and provide critical insight into an individual’s risk for atherosclerotic cardiovascular disease (ASCVD).

The standard lipid panel includes four primary components: total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. LDL-C—often termed “bad cholesterol”—is the principal carrier of cholesterol to arterial walls; elevated levels promote plaque formation and are strongly associated with myocardial infarction and ischemic stroke. HDL-C—commonly called “good cholesterol”—facilitates reverse cholesterol transport, helping remove excess cholesterol from peripheral tissues and delivering it to the liver for excretion. Triglycerides represent circulating fatty acids esterified to glycerol; persistently high concentrations (>150 mg/dL or 1.7 mmol/L) correlate with increased ASCVD risk, especially when accompanied by low HDL-C or insulin resistance.

In select clinical scenarios—such as suspected familial hypercholesterolemia, borderline LDL-C values, or residual risk assessment—additional markers may be measured. These include apolipoprotein B (ApoB), which quantifies the total number of atherogenic particles (including LDL, VLDL, and Lp(a)), and lipoprotein(a) [Lp(a)], a genetically determined, prothrombotic, and proinflammatory lipoprotein independently linked to premature coronary artery disease and calcific aortic stenosis. Non-HDL cholesterol—calculated as total cholesterol minus HDL-C—is also increasingly recommended as a secondary target, particularly in patients with hypertriglyceridemia, since it captures all atherogenic lipoprotein particles.

Interpretation of results must always be contextualized within the patient’s overall cardiovascular risk profile—including age, sex, smoking status, blood pressure, diabetes mellitus, family history, and presence of chronic kidney disease—rather than relying on isolated numeric thresholds. Clinical guidelines from major societies, including the American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS), emphasize risk-based treatment goals over fixed cutoffs for most adults.